Loading…
TriSalus Life Sciences, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -56.4% over 5Y.
today you would have $437.06▼ -56.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $6.98 | $5.01 | $8.45 | $10.03 | $9.88 | |
| P/S | 7.5x | 9.5x | 5.5x | 12.2x | 0.3x | — |
| EPS | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — | |
| Profit margin | -211.39% | -86.88% | -102.09% | -320.69% | -380.60% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CVCapsoVision, Inc | $5.93 | — | 22.5x | — | -335.06% | $296.78M |
| IMRXImmuneering Corp | $4.61 | — | 1.6x | — | -52.15% | $298.26M |
| TTRXTurn Therapeutics Inc. | $9.84 | — | 427.8x | — | -686.28% | $298.82M |
| AMRNAmarin Corp Plc\uk | $13.97 |
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Company description provided by Yahoo Finance.
| — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.7x |
| — |
| -5.97% |
| $295.09M |
| TMCITreace Medical Concepts Inc | $4.65 | — | 4.5x | — | -71.99% | $302.41M |
| LABStandard Biotools Inc | $0.74 | — | 0.5x | — | -11.18% | $291.29M |